Vol. 4, Issue 1, Part A (2024)

Immune thrombocytopenia (ITP) in pediatric patients presents a multifaceted challenge, particularly when the condition persists beyond the acute phase, leading to increased risk of bleeding and potential progression to chronicity. Romiplostim, a thrombopoietin receptor agonist, has emerged as a promising therapeutic option to address the unmet needs of these patients. This review delves into the current body of evidence regarding romiplostim's efficacy and safety profile in pediatric patients with persistent ITP. It provides a nuanced understanding of romiplostim's role in preventing chronicity, enhancing platelet counts, minimizing bleeding events, and improving quality of life in this vulnerable population.